The Placement of Aortic Transcatheter Valves (PARTNER) trial demonstrated that transcatheter aortic valve replacement (TAVR) for high-risk patients with aortic stenosis resulted in similar outcomes at 1, 2 and 3 years compared with surgical aortic valve replacement (SAVR). The present study reports the 5-year outcomes of this trial. The study enrolled 699 patients who were […]
Tag: Aortic stenosis
2-year PARTNER data published
While the last 5 years have seen an incredible expansion in the use of transcatheter aortic-vlave replacement (TAVR) for patients with severe aortic stenosis who are not considered suitable for surgery, long-term outcomes data remain scant. The randomised Placement of Aortic Transcatheter Valves (PARTNER) trial found that, as compared with standard therapy, TAVR reduced symptoms […]
SEAS apart: no role for lipid lowering in aortic valve disease
Calcific aortic stenosis shares risk factors with coronary heart disease and predicts death and MI without the need for large gradients. Hyperlipidaemia has been suggested as a risk factor for the development of aortic stenosis but to date lipid lowering studies have demonstrated conflicting results. […]